Comparison of two strategies for initiating ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Comparison of two strategies for initiating renal replacement therapy in the intensive care unit: study protocol for a randomized controlled trial (akiki)
Author(s) :
Gaudry, Stéphane [Auteur]
Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables [ECEVE (U1123 / UMR_S_1123)]
Hajage, David [Auteur]
Hôpital Louis Mourier - AP-HP [Colombes]
Schortgen, Frédérique [Auteur]
Centre Hospitalier Intercommunal de Créteil [CHIC]
Martin-Lefevre, Laurent [Auteur]
Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon [CHD Vendée]
Tubach, Florence [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Pons, Bertrand [Auteur]
CHU Pointe-à-Pitre/Abymes [Guadeloupe]
Boulet, Eric [Auteur]
Centre Hospitalier René Dubos [Pontoise]
Boyer, Alexandre [Auteur]
Hôpital Pellegrin
Lerolle, Nicolas [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Chevrel, Guillaume [Auteur]
Carpentier, Dorothee [Auteur]
CHU Rouen
Lautrette, Alexandre [Auteur]
CHU Gabriel Montpied [Clermont-Ferrand]
Bretagnol, Anne [Auteur]
Centre Hospitalier Régional d'Orléans [CHRO]
Mayaux, Julien [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Thirion, Marina [Auteur]
Markowicz, Philippe [Auteur]
Thomas, Guillemette [Auteur]
Hôpital Nord [CHU - APHM]
Dellamonica, Jean [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Richecoeur, Jack [Auteur]
Darmon, Michael [Auteur]
Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] [CHU ST-E]
De Prost, Nicolas [Auteur]
Hôpital Henri Mondor
Yonis, Hodane [Auteur]
Hôpital de la Croix-Rousse [CHU - HCL]
Megarbane, Bruno [Auteur]
Université Paris Diderot, Sorbonne Paris Cité, Paris, France
Loubieres, Yann [Auteur]
CHI Poissy-Saint-Germain
Blayau, Clarisse [Auteur]
Maizel, Julien [Auteur]
CHU Amiens-Picardie
Zuber, Benjamin [Auteur]
Centre Hospitalier de Versailles André Mignot [CHV]
Nseir, Saad [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center (LIRIC) - U995
Bige, Naike [Auteur]
CHU Saint-Antoine [AP-HP]
Hoffmann, Isabelle [Auteur]
CIC - CHU Bichat
Ricard, Jean-Damien [Auteur]
Hôpital Louis Mourier - AP-HP [Colombes]
Dreyfuss, Didier [Auteur]
Hôpital Louis Mourier - AP-HP [Colombes]
Epidémiologie Clinique et Evaluation Economique Appliquées aux Populations Vulnérables [ECEVE (U1123 / UMR_S_1123)]
Hajage, David [Auteur]
Hôpital Louis Mourier - AP-HP [Colombes]
Schortgen, Frédérique [Auteur]
Centre Hospitalier Intercommunal de Créteil [CHIC]
Martin-Lefevre, Laurent [Auteur]
Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon [CHD Vendée]
Tubach, Florence [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Pons, Bertrand [Auteur]
CHU Pointe-à-Pitre/Abymes [Guadeloupe]
Boulet, Eric [Auteur]
Centre Hospitalier René Dubos [Pontoise]
Boyer, Alexandre [Auteur]
Hôpital Pellegrin
Lerolle, Nicolas [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Chevrel, Guillaume [Auteur]
Carpentier, Dorothee [Auteur]
CHU Rouen
Lautrette, Alexandre [Auteur]
CHU Gabriel Montpied [Clermont-Ferrand]
Bretagnol, Anne [Auteur]
Centre Hospitalier Régional d'Orléans [CHRO]
Mayaux, Julien [Auteur]
CHU Pitié-Salpêtrière [AP-HP]
Thirion, Marina [Auteur]
Markowicz, Philippe [Auteur]
Thomas, Guillemette [Auteur]
Hôpital Nord [CHU - APHM]
Dellamonica, Jean [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Richecoeur, Jack [Auteur]
Darmon, Michael [Auteur]
Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] [CHU ST-E]
De Prost, Nicolas [Auteur]
Hôpital Henri Mondor
Yonis, Hodane [Auteur]
Hôpital de la Croix-Rousse [CHU - HCL]
Megarbane, Bruno [Auteur]
Université Paris Diderot, Sorbonne Paris Cité, Paris, France
Loubieres, Yann [Auteur]
CHI Poissy-Saint-Germain
Blayau, Clarisse [Auteur]
Maizel, Julien [Auteur]
CHU Amiens-Picardie
Zuber, Benjamin [Auteur]
Centre Hospitalier de Versailles André Mignot [CHV]
Nseir, Saad [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lille Inflammation Research International Center (LIRIC) - U995
Bige, Naike [Auteur]
CHU Saint-Antoine [AP-HP]
Hoffmann, Isabelle [Auteur]
CIC - CHU Bichat
Ricard, Jean-Damien [Auteur]
Hôpital Louis Mourier - AP-HP [Colombes]
Dreyfuss, Didier [Auteur]
Hôpital Louis Mourier - AP-HP [Colombes]
Journal title :
Trials
Abbreviated title :
Trials
Volume number :
16
Publication date :
2015-04-17
ISSN :
1745-6215
English keyword(s) :
Renal replacement therapy
Acute kidney injury
Treatment outcome
Critical care
Mesh:Decision Support Techniques
Mesh:Acute Kidney Injury/diagnosis
Mesh:Critical Illness
Mesh:Acute Kidney Injury/blood
Mesh:Clinical Protocols
Mesh:Biomarkers/blood
Mesh:Acute Kidney Injury/therapy*
Mesh:Acute Kidney Injury/physiopathology
Mesh:Acute Kidney Injury/mortality
Mesh:Patient Selection
Mesh:Intensive Care Units*
Mesh:Injury Severity Score
Mesh:Risk Assessment
Mesh:Risk Factors
Mesh:Time Factors
Mesh:Time-to-Treatment*
Mesh:Treatment Outcome
Mesh:Humans
Mesh:France
Mesh:Research Design
Mesh:Renal Replacement Therapy/mortality
Mesh:Renal Replacement Therapy/methods*
Mesh:Renal Replacement Therapy/adverse effects
Mesh:Prospective Studies
Mesh:Predictive Value of Tests
Acute kidney injury
Treatment outcome
Critical care
Mesh:Decision Support Techniques
Mesh:Acute Kidney Injury/diagnosis
Mesh:Critical Illness
Mesh:Acute Kidney Injury/blood
Mesh:Clinical Protocols
Mesh:Biomarkers/blood
Mesh:Acute Kidney Injury/therapy*
Mesh:Acute Kidney Injury/physiopathology
Mesh:Acute Kidney Injury/mortality
Mesh:Patient Selection
Mesh:Intensive Care Units*
Mesh:Injury Severity Score
Mesh:Risk Assessment
Mesh:Risk Factors
Mesh:Time Factors
Mesh:Time-to-Treatment*
Mesh:Treatment Outcome
Mesh:Humans
Mesh:France
Mesh:Research Design
Mesh:Renal Replacement Therapy/mortality
Mesh:Renal Replacement Therapy/methods*
Mesh:Renal Replacement Therapy/adverse effects
Mesh:Prospective Studies
Mesh:Predictive Value of Tests
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
BACKGROUND: There is currently no validated strategy for the timing of renal replacement therapy (RRT) for acute kidney injury (AKI) in the intensive care unit (ICU) when short-term life-threatening metabolic abnormalities ...
Show more >BACKGROUND: There is currently no validated strategy for the timing of renal replacement therapy (RRT) for acute kidney injury (AKI) in the intensive care unit (ICU) when short-term life-threatening metabolic abnormalities are absent. No adequately powered prospective randomized study has addressed this issue to date. As a result, significant practice heterogeneity exists and may expose patients to either unnecessary hazardous procedures or undue delay in RRT. METHODS: This is a multicenter, prospective, randomized, open-label parallel-group clinical trial that compares the effect of two RRT initiation strategies on overall survival of critically ill patients receiving intravenous catecholamines or invasive mechanical ventilation and presenting with AKI classification stage 3 (KDIGO 2012). In the 'early' strategy, RRT is initiated immediately. In the 'delayed' strategy, clinical and metabolic conditions are closely monitored and RRT is initiated only when one or more events (severity criteria) occur, including: oliguria or anuria for more than 72 hours after randomization, serum urea concentration >40 mmol/l, serum potassium concentration >6 mmol/l, serum potassium concentration >5.5 mmol/l persisting despite medical treatment, arterial blood pH <7.15 in a context of pure metabolic acidosis (PaCO2 < 35 mmHg) or in a context of mixed acidosis with a PaCO2 ≥ 50 mmHg without possibility of increasing alveolar ventilation, acute pulmonary edema due to fluid overload despite diuretic therapy leading to severe hypoxemia requiring oxygen flow rate >5 l/min to maintain SpO2 > 95% or FiO2 > 50% under invasive or noninvasive mechanical ventilation. The primary outcome measure is overall survival, measured from randomization (D0) until death, regardless of the cause. The minimum follow-up duration for each patient will be 60 days. Two interim analyses are planned, blinded to group allocation. It is expected that there will be 620 subjects in all. CONCLUSIONS: The AKIKI study will be one of the very few large randomized controlled trials evaluating mortality according to the timing of RRT in critically ill patients with AKI classification stage 3 (KDIGO 2012). Results should help clinicians decide when to initiate RRT. BACKGROUND: ClinicalTrials.gov NCT01932190.Show less >
Show more >BACKGROUND: There is currently no validated strategy for the timing of renal replacement therapy (RRT) for acute kidney injury (AKI) in the intensive care unit (ICU) when short-term life-threatening metabolic abnormalities are absent. No adequately powered prospective randomized study has addressed this issue to date. As a result, significant practice heterogeneity exists and may expose patients to either unnecessary hazardous procedures or undue delay in RRT. METHODS: This is a multicenter, prospective, randomized, open-label parallel-group clinical trial that compares the effect of two RRT initiation strategies on overall survival of critically ill patients receiving intravenous catecholamines or invasive mechanical ventilation and presenting with AKI classification stage 3 (KDIGO 2012). In the 'early' strategy, RRT is initiated immediately. In the 'delayed' strategy, clinical and metabolic conditions are closely monitored and RRT is initiated only when one or more events (severity criteria) occur, including: oliguria or anuria for more than 72 hours after randomization, serum urea concentration >40 mmol/l, serum potassium concentration >6 mmol/l, serum potassium concentration >5.5 mmol/l persisting despite medical treatment, arterial blood pH <7.15 in a context of pure metabolic acidosis (PaCO2 < 35 mmHg) or in a context of mixed acidosis with a PaCO2 ≥ 50 mmHg without possibility of increasing alveolar ventilation, acute pulmonary edema due to fluid overload despite diuretic therapy leading to severe hypoxemia requiring oxygen flow rate >5 l/min to maintain SpO2 > 95% or FiO2 > 50% under invasive or noninvasive mechanical ventilation. The primary outcome measure is overall survival, measured from randomization (D0) until death, regardless of the cause. The minimum follow-up duration for each patient will be 60 days. Two interim analyses are planned, blinded to group allocation. It is expected that there will be 620 subjects in all. CONCLUSIONS: The AKIKI study will be one of the very few large randomized controlled trials evaluating mortality according to the timing of RRT in critically ill patients with AKI classification stage 3 (KDIGO 2012). Results should help clinicians decide when to initiate RRT. BACKGROUND: ClinicalTrials.gov NCT01932190.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Submission date :
2019-12-09T18:17:18Z
2020-06-02T08:54:20Z
2020-06-02T08:54:20Z
Files
- s13063-015-0718-x.pdf
- Version éditeur
- Open access
- Access the document